EU NSCLC Therapeutics Market Analysis

$3,500.00$7,500.00

  • Type: Therapeutics Area
  • Published : January 2022
  • Region: Europe
  • Country: Other
  • Report ID : 4988

  • Format: PPT, PDF

EU NSCLC Therapeutics Market Analysis: Segmented by Therapy, Distribution Channel, Cancer Type – Growth, Market Size, Future Prospects & Competitive Analysis, 2020 – 2028

Clear
SKU: 4988 Categories: ,

Report Description of the EU NSCLC Therapeutics Market Analysis

Research Scope and Assumption

  • The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
  • The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
  • We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
  • All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
  • Inflation has not been accounted for in order to estimate and forecast the market
  • Numbers may not add up due to rounding off

Reason to buy the report:

  • Facilitate decision-making based on strong current and forecast data for EU NSCLC Therapeutics  Market  Analysis
  • Develop strategies based on the latest regulatory framework
  • Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
  • Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the EU NSCLC Therapeutics  Market  Analysis
  • Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
  • To strategically profile key players and comprehensively analyze their market shares and core competencies
  • We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

EU NSCLC Therapeutics Market Analysis Executive Summary

A common cancer treatment is non-small cell lung cancer therapy, or NSCLC. NSCLC has the potential to metastasize in human bones, making it difficult to diagnose and treat. Non-small cell lung cancer accounts for 90 percent of all lung cancers. NSCLC therapies are designed to treat the cancer from its early stages to its terminal stage. Specialized proteins and simple chemistry combine to form them. A growing awareness due to several government initiatives has helped boost the development of the global non-small cell lung cancer therapeutics market.

Market Size and Key Findings

The EU NSCLC Therapeutics Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 9.5% during the forecast period.

Europe, Germany is forecast to grow at approximately 9.5% CAGR.

Market Dynamics

Market Growth Drivers Analysis

The growing demand for targeted therapies, presence of highly efficient drugs, increase in geriatric population, and rise in the prevalence of unhealthy lifestyles are the prominent factors that drive the lung cancer therapeutics market. The arrival of Nano medicine to treat lung cancer and the growing approvals in the lung cancer therapeutics market fuel the opportunities for the rise in the lung cancer therapeutics market.

Market Restraints

In contrast, poor cancer diagnostic facilities in many countries and the adverse effects of chemotherapies are the factors that are likely to restrain the global lung cancer therapeutics market.

Competitive Landscape

Key Players

The vendor landscape of the non-small cell lung cancer therapeutics market is a fragmented one because of the presence of numerous leading companies. Some of the most prominent brands in the global market are AstraZeneca Plc., Pfizer Inc., Eli Lilly and Company, Boehringer Ingelheim, Squibb, and Bristol Myers among others.

Products in Pipeline

In terms of pipeline, the global non-small cell lung cancer therapeutics market can be segmented in early stage (phase I and II) and late stage (phase III). In terms of class of drugs, the global market is further segmented into PD-1/PD-L1 inhibitor, kinase inhibitor, microtubule stabilizer, EGFR inhibitor, folate antimetabolites, and angiogenesis inhibitors.

Notable Recent Deals

  • Tagrisso is expected to be dominate the market because of it selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations, also its use as first-line therapy in NSCLC does not lead to T790M mutations.
  • Keytruda with physician’s familiarities and established clinical profile expected to take more share compared to canakinumab.
  • The highest revenue is expected to be generated by Keytruda (pembrolizumab) by 2030.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The current scenario of therapeutics for NSCLC is mainly based on the use of targeted therapies and immunotherapy’s. Especially the current paradigm is mainly associated with treatment specific to mutations that occur in NSCLC. NSCLC is characterized by the availability of a high number of branded therapies such as Keytruda, Opdivo, Tecentriq, Tagrisso, and others. Due to the high costs, some of the therapies are not able to show their cost-effectiveness and are unable to get a recommendation by assessment agencies. So, the access and reimbursement scenario of drugs for NSCLC is not easy as cost-effectiveness is a major barrier for therapies in NSCLC.

The recommendation of some drugs by NICE which are approved for NSCLC are Opdivo (Nivolumab), Tagrisso (osimertinib), Alunbrig (brigatinib), Keytruda (pembrolizumab), Nintedanib in combination with docetaxel, Durvalumab, Atezolizumab with carboplatin and nab-paclitaxel, among others.

1. Report Description of the EU NSCLC Therapeutics Market Analysis
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. EU NSCLC Therapeutics Market Analysis Executive Summary
2.1 EU NSCLC Therapeutics Market Analysis – Industry Snapshot & key buying criteria, 2020-2028
2.2 Market Size, Growth Prospects and Key findings
3. Market Dynamics of EU NSCLC Therapeutics Market Analysis
3.1 Market Growth Drivers Analysis
3.1.1 Increase in geriatric population
3.1.2 Rise in the prevalence of unhealthy lifestyles
3.2 Market Restraints Analysis
3.2.1 Poor cancer diagnostic facilities
3.2.2 Side effects of cancer therapies
3.3 Covid-19 Market Impact Analysis
4. EU NSCLC Therapeutics Market Segmentation
4.1 By Therapy:
4.1.1 Targeted Therapy
4.1.2 Immunotherapy
4.1.3 Chemotherapy
4.2 By Distribution Channel:
4.2.1 Retail Pharmacies
4.2.2 Hospital Pharmacies
4.2.3 Online Pharmacies
4.2.4 Other Pharmacies
4.3 By Cancer Type:
4.3.1 Adenocarcinoma
4.3.2 Squamous cell carcinoma
4.3.3 Large cell carcinoma
5. EU NSCLC Therapeutics Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Top Market Players
6.2 Products in Pipeline
6.3 R&D Initiatives in NSCLC Therapeutics Market
6.4 Notable recent deals in NSCLC Therapeutics Market
6.4.1 Joint Ventures
6.4.2 Partnerships
6.4.3 Mergers & Acquisitions
6.4.4 Strategic divestments
7. Key Company Profiles
7.1 Genentech Inc. Company overview
Product & Services, Strategies & Financials
7.2 F. Hoffmann-La Roche Ltd. Company overview
Product & Services, Strategies & Financials
7.3 AstraZeneca Company overview
Product & Services, Strategies & Financials
7.4 Eli Lilly and Company overview
Product & Services, Strategies & Financials
7.5 Novartis Company overview
Product & Services, Strategies & Financials
7.6 Pfizer Inc. Company overview
Product & Services, Strategies & Financials
7.7 Sun Pharmaceutical Industries Ltd. Company overview
Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
9. Factors Driving Future Growth
9.1 New Trends and Development of NSCLC Therapeutics market
9.2 Future Opportunities
10. Strategic Recommendations

EU NSCLC Therapeutics Market Analysis Segmentation

By Therapy:

Based on the therapy, the non-small cell lung cancer therapeutics market segments include targeted therapy (which can be further sub-segmented into bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, osimertinib, and others), immunotherapy (which can be further sub-segmented durvalumab, nivolumab, atezolizumab, pembrolizumab), and chemotherapy. The targeted therapy segment dominated the global NSCLC therapeutics market in 2018.

By Distribution Channel:

Based on the distribution channel, the market segments include hospital pharmacies, retail pharmacies, online pharmacies, and others.

By Cancer Type:

Based on cancer type, the non-small cell lung cancer therapeutics market segments include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

To request a free sample copy this report, please complete the form below.

    We value your inquiry and offer free customization with every report to fulfil your exact research needs.

    This website is secure and your personal details are safe.



    This report addresses

    • Market intelligence to enable effective decision making
    • Growth opportunities and trend analysis
    • Competitive benchmarking
    • Historical data & forecasts
    • Regional opportunities

    Need more?

    • Speak to our analyst to know how this research was put together
    • Add more countries or regions as part of customisation
    • Understand how this report can have direct impact on your revenue

    Get a custom report based on your requirements